Business Details

Full description and what we offer

Crossbow Therapeutics is a biopharmaceutical company headquartered in Cambridge, Massachusetts at 1030 Massachusetts Ave. Suite 210. Founded with $80 million in Series A financing (July 2023), they're building a new class of antibody therapies designed to expand the reach of cancer treatment.

Unlike traditional approaches, Crossbow's platform targets intracellular cancer antigens by developing T-Cell Receptor mimetic (TCRm) antibodies. These highly potent, highly accurate molecules bind to tumor-specific peptides presented by Major Histocompatibility Complex (MHC)—essentially mimicking how a patient's own T-cells would recognize cancer.

The company chose its name because next-generation therapies embody the precision and power of a crossbow: unparalleled accuracy and potency striking tumor cells like bolts at their target.

Program	Target	Approach	Indication	Status
CBX-250	Cathepsin G	T-Cell Engager	AML, MDS, CML	Clinical
CBX-663	TERT	T-Cell Engager	Multi-cancer solid tumors	IND-enabling
Undisclosed	Multiple targets	T-Cell Engager	Solid & heme malignancies	Discovery

CBX-250 milestone (September 2025): First patient dosed in Phase 1 trial for myeloid malignancies.

Crossbow's three-step approach:

1. Identify & validate the most promising cancer antigens from an expanding universe of targets 2. Create high-quality TCR-mimetics using proprietary technology, developing potent antibodies targeting tumor-specific peptides 3. Develop innovative products by incorporating TCRm antibodies into T-cell engagers and other immunotherapies, optimizing manufacturability and potency

For physicians treating patients with serious or life-threatening conditions who cannot enroll in clinical trials, Crossbow maintains a compassionate use policy. Requests for CBX-250 access should be submitted to [email protected].

Led by CEO Briggs Morrison, M.D. and Co-founder/Chairman Todd Foley, M.B.A., the team includes international experts in drug development, antibody engineering, and translational medicine. Scientific Advisory Board members represent leading voices in immunotherapy and oncology.